Gideon M Hirschfield, Katherine Arndtz, Amanda Kirkham, Yung-Yi Chen, Richard Fox, Anna Rowe, Jessica Douglas-Pugh, Douglas Thorburn, Eleanor Barnes, Guruprasad P Aithal, Diana Hull, Khushpreet Bhandal, Kathryn Olsen, Paul Woodward, Siân Lax, Philip Newsome, David J Smith, Antero Kallio, David H Adams, Victoria Homer, Chris J Weston
BACKGROUND: Primary sclerosing cholangitis is a progressive inflammatory liver disease characterized by biliary and liver fibrosis. Vascular adhesion protein-1 (VAP-1) is important in the inflammatory process driving liver fibrosis. We evaluated the safety and efficacy of VAP-1 blockade with a monoclonal antibody (timolumab, BTT1023) in patients with primary sclerosing cholangitis. METHODS: BUTEO was a prospective, single-arm, open-label, multicenter, phase II trial, conducted in 6 centers in the United Kingdom...
May 1, 2024: Hepatology Communications